Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)16.49bn
- Net income in MXN1.10bn
- Incorporated1996
- Employees1.59k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cansino Biologics Inc | 857.61m | -3.68bn | 17.56bn | 1.49k | -- | 0.8246 | -- | 20.48 | -6.46 | -6.46 | 1.50 | 22.94 | 0.0332 | 2.37 | 0.4619 | 248,227.30 | -18.93 | -4.27 | -26.69 | -5.60 | -253.78 | -- | -569.97 | -27.72 | 1.86 | -- | 0.3381 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Pacira Biosciences Inc | 12.31bn | 1.27bn | 17.65bn | 711.00 | 16.20 | 1.09 | 6.74 | 1.43 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Towa Pharmaceutical Co Ltd | 26.14bn | 1.85bn | 18.17bn | 4.59k | 9.36 | 0.9709 | 4.65 | 0.695 | 328.58 | 328.58 | 4,630.88 | 3,167.26 | 0.5684 | 1.51 | 3.70 | 49,680,470.00 | 4.03 | 4.21 | 5.03 | 5.63 | 35.70 | 39.23 | 7.10 | 7.23 | 1.46 | -- | 0.5649 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
| Genomma Lab Internacional SAB de CV | 16.49bn | 1.10bn | 18.19bn | 1.59k | 15.57 | 1.72 | 13.49 | 1.10 | 1.14 | 1.14 | 17.28 | 10.34 | 0.764 | 2.90 | 3.66 | 10,095,660.00 | 5.09 | 5.79 | 8.21 | 8.64 | 62.23 | 61.70 | 6.67 | 7.88 | 1.32 | 2.55 | 0.3945 | 16.85 | -2.10 | 6.90 | -21.90 | -0.4465 | -26.37 | -- |
| AIM Vaccine Co Ltd | 2.95bn | -3.23bn | 18.19bn | 1.62k | -- | 2.01 | -- | 6.17 | -1.15 | -1.15 | 1.05 | 3.23 | -- | -- | -- | 785,575.50 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 15.64bn | 4.95bn | 18.33bn | 4.62k | 3.70 | 0.9298 | 3.28 | 1.17 | 2.43 | 2.43 | 7.69 | 9.69 | 0.5111 | 3.62 | 4.09 | 1,464,419.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Marksans Pharma Ltd | 4.70bn | 676.70m | 18.50bn | 1.40k | 27.30 | 4.15 | 22.03 | 3.94 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Strides Pharma Science Ltd | 8.74bn | -269.28m | 18.54bn | 2.85k | -- | 4.04 | 119.12 | 2.12 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Tarsus Pharmaceuticals Inc | 768.72m | -2.68bn | 18.71bn | 244.00 | -- | 3.76 | -- | 24.34 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Jianmin Pharmaceutical Group Co Ltd | 10.36bn | 1.30bn | 18.71bn | 2.50k | 14.40 | 3.20 | -- | 1.81 | 3.41 | 3.41 | 27.26 | 15.35 | 1.04 | 5.81 | 4.34 | 1,669,960.00 | 13.09 | 10.87 | 23.66 | 19.11 | 43.70 | 43.04 | 12.56 | 9.32 | 1.26 | -- | 0.1891 | 37.15 | 15.72 | 14.28 | 27.78 | 45.05 | 8.77 | 43.10 |
| Jinyu Bio-Technology Co Ltd | 3.93bn | 701.90m | 18.73bn | 1.65k | 26.00 | 1.33 | -- | 4.77 | 0.2588 | 0.2588 | 1.44 | 5.05 | 0.2365 | 2.06 | 1.98 | 956,543.20 | 4.09 | 4.82 | 4.79 | 5.68 | 57.97 | 58.78 | 17.28 | 19.91 | 3.33 | -- | 0.0043 | 36.41 | 4.55 | -3.37 | 34.63 | -17.77 | -12.92 | -25.56 |
| Kissei Pharmaceutical Co Ltd | 8.67bn | 1.28bn | 18.77bn | 1.78k | 13.46 | 0.667 | 10.53 | 2.17 | 246.57 | 246.57 | 1,669.95 | 4,977.43 | 0.3135 | 1.56 | 2.94 | 42,483,980.00 | 4.68 | 3.61 | 5.05 | 3.90 | 49.41 | 49.47 | 14.94 | 12.69 | 4.43 | -- | 0.0078 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
Data as of Jul 22 2024. Currency figures normalised to Genomma Lab Internacional SAB de CV's reporting currency: Mexican New Peso MXN
21.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 May 2024 | 48.62m | 4.77% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 28.99m | 2.84% |
| Skagen AS (Investment Management)as of 31 Mar 2024 | 25.00m | 2.45% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 04 Jul 2024 | 22.54m | 2.21% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 21.67m | 2.12% |
| Wellington Management Co. LLPas of 31 May 2024 | 17.01m | 1.67% |
| MFS International (UK) Ltd.as of 31 May 2024 | 16.34m | 1.60% |
| Lemanik Asset Management SAas of 30 Jun 2023 | 15.86m | 1.56% |
| Invesco Asset Management Ltd.as of 28 Jun 2024 | 12.70m | 1.25% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 12.02m | 1.18% |
More ▼
Data from 31 Mar 2024 - 18 Jul 2024Source: FactSet Research Systems Inc.
